A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study
- 31 May 2013
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 63 (5), 927-935
- https://doi.org/10.1016/j.eururo.2012.09.007
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2005
- Risk of Fracture after Androgen Deprivation for Prostate CancerNew England Journal of Medicine, 2005
- Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapyCancer, 2004
- Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation TherapyJournal of Urology, 2002
- SKELETAL FRACTURE ASSOCIATED WITH ANDROGEN SUPPRESSION INDUCED OSTEOPOROSIS: THE CLINICAL INCIDENCE AND RISK FACTORS FOR PATIENTS WITH PROSTATE CANCERJournal of Urology, 2001
- Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancerUrology, 2001
- Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancerBJU International, 2000
- Androgen deprivation therapy for prostate cancer results in significant loss of bone densityUrology, 1999
- Osteoporosis After Orchiectomy for Prostate CancerJournal of Urology, 1997
- Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinomaCancer, 1997